OMCL News Alert Omnicell Inc (OMCL) 32.63 12/17/2014 02:22:0

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Omnicell Inc (OMCL) 32.63 $OMCL

16.6% Return Seen to Date on SmarTrend Omnicell Call (OMCL)
Comtex SmarTrend(R) - Wed Dec 10, 9:27AM CST
SmarTrend identified an Uptrend for Omnicell (NASDAQ:OMCL) on October 28th, 2014 at $29.08. In approximately 1 month, Omnicell has returned 16.64% as of today's recent price of $33.92.
OMCL: 32.63 (-0.27)

Strong And Under The Radar Today: Omnicell (OMCL)
at The Street - Fri Dec 05, 8:50AM CST
Trade-Ideas LLC identified Omnicell (OMCL) as a strong and under the radar candidate
OMCL: 32.63 (-0.27)

Omnicell Reveals "Take on Tomorrow" Initiative at ASHP Mid-Year Meeting
PR Newswire - Thu Dec 04, 7:00AM CST
Omnicell, Inc., (NASDAQ: OMCL), today announced the "Take on Tomorrow" initiative for 2015, demonstrating the company's commitment to solve medication management compliance challenges, and expand the reach of central pharmacy to satellite and post-acute settings. Omnicell's presence at the American Society of Health-System Pharmacists 2014 Mid-Year Meeting in Anaheim is highlighted by multiple events and demonstrations to illustrate what "tomorrow" will look like as pharmacists advance their role in driving enriched patient care.
OMCL: 32.63 (-0.27)

Don't Miss Today's Strong And Under The Radar Stock: Omnicell (OMCL)
at The Street - Wed Nov 26, 8:48AM CST
Trade-Ideas LLC identified Omnicell (OMCL) as a strong and under the radar candidate
OMCL: 32.63 (-0.27)

Omnicell To Present At The 26th Annual Piper Jaffray Health Care Conference
PR Newswire - Tue Nov 25, 7:00AM CST
Omnicell, Inc. (NASDAQ:OMCL) a leading provider of medication and supply management solutions and analytics software for healthcare facilities, today announced they will present at the 26th Annual Piper Jaffray Health Care Conference at the New York Palace Hotel, New York, NY.
OMCL: 32.63 (-0.27)

Omnicell Offers Advanced OT Automation at Hospital in Riyadh - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 19, 2:30PM CST
Per the deal, KFSH&RC will now use Omnicell's (OMCL) Anesthesia Workstation in 37 operating theatres across the hospital thus expanding its installation of Omnicell products
ANIP: 55.08 (+1.32), AMAG: 40.30 (+1.29), OMCL: 32.63 (-0.27), AFFX: 8.90 (+0.10)

Omnicell and King Faisal Specialist Hospital and Research Centre Collaborate to Deliver Excellence in Automation
PR Newswire - Tue Nov 18, 7:00AM CST
Omnicell, Inc. (NASDAQ: OMCL) a leading provider of medication and supply management solutions and analytics software for health care facilities, today announced that King Faisal Specialist Hospital and Research Center (KFSH&RC) in Riyadh has now expanded its installation of Omnicell products to include full use of Omnicell's Anesthesia Workstation(TM) in 37 operating theatres throughout the hospital to be the first hospital in the region fully automating its operating room medication and supply management. The health care facility replaced a competitive legacy system with the Omnicell Anesthesia Workstation due to Omnicell's experienced local support capabilities and the company's track record for continually improving its technology to meet the needs of growing health care systems. KFSH&RC also recently selected Omnicell as its automation partner for the new 23-floor King Abdullah Centre for Oncology and Liver Diseases (KACO&LD).
OMCL: 32.63 (-0.27)

Earnings Look Back: Omnicell Is Up 7.1% Since Reporting Quarterly Results 2 Weeks Ago (OMCL)
Comtex SmarTrend(R) - Mon Nov 17, 1:22PM CST
Two weeks ago on October 30th, 2014 Omnicell (NASDAQ:OMCL) reported earnings and analysts, on average, expected earnings of $0.31 on sales of $105.9 million. Omnicell actually reported earnings of $0.30 per share on sales of $112.5 million, missing EPS estimates by $0.01 and beating revenue estimates by $6.7 million. Since the company's report, shares of Omnicell have risen from $30.11 to $32.26, representing a gain of 7.1% in the past 18 days.
OMCL: 32.63 (-0.27)

Omnicell Has Returned 11.9% Since SmarTrend Recommendation (OMCL)
Comtex SmarTrend(R) - Fri Nov 14, 10:05AM CST
SmarTrend identified an Uptrend for Omnicell (NASDAQ:OMCL) on October 28th, 2014 at $29.08. In approximately 2 weeks, Omnicell has returned 11.90% as of today's recent price of $32.54.
OMCL: 32.63 (-0.27)

Omnicell Reports Mixed Q3, Positive on Surgichem Buyout - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 2:00PM CST
On Nov 6, 2014, we issued an updated research report on Omnicell Inc. (OMCL).
BSX: 12.95 (+0.15), ICUI: 80.40 (+0.08), ABAX: 56.69 (+0.47), OMCL: 32.63 (-0.27)

Earnings Flashback: Since Reporting Quarterly Results 1 Week Ago Omnicell Is Up 5.9% (OMCL)
Comtex SmarTrend(R) - Mon Nov 10, 12:13PM CST
11 days ago, on October 30th, 2014, Omnicell (NASDAQ:OMCL) reported its earnings. Analysts, on average, expected earnings of $0.31 per share on sales of $105.9 million. The company actually reported EPS of $0.30 on sales of $112.5 million, missing EPS estimates by $0.01 and beating revenue estimates by $6.7 million. Since the company's report, shares of Omnicell have risen from $30.11 to $31.89, representing a gain of 5.9% in the past 11 days.
OMCL: 32.63 (-0.27)

Omnicell Earnings Hit by High Tax, User Addition Aids Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 11:27AM CST
On Nov 7, 2014, we issued an updated research report on Omnicell Inc. (OMCL).
BSX: 12.95 (+0.15), ICUI: 80.40 (+0.08), ABAX: 56.69 (+0.47), OMCL: 32.63 (-0.27)

Update: Omnicell Q3 Earnings Send Shares Soaring
Marshall Hargrave - at Seeking Alpha - Wed Nov 05, 9:57AM CST

OMCL: 32.63 (-0.27)

Omnicell To Present At The 2014 Stephens Inc. Fall Investment Conference
PR Newswire - Wed Nov 05, 7:17AM CST
Omnicell, Inc. (NASDAQ:OMCL), a leading provider of medication and supply management solutions and analytics software for healthcare facilities, today announced it will present at the 2014 Stephens Inc. Fall Investment Conference at the New York Palace Hotel, New York, NY.
OMCL: 32.63 (-0.27)

Omnicell Launches Its First Fully Automated Multimed Packing Solution, Driving Workflow Efficiency, Patient Adherence, and Pharmacy Growth
PR Newswire - Wed Nov 05, 7:00AM CST
Omnicell, Inc., (NASDAQ:OMCL), today announced the company's first fully automated multimed packing solution to assist pharmacists in improving their patients' medication adherence. The Omnicell M5000 system is designed to automatically pack, seal, verify and label multimed blister cards for institutional pharmacies serving long term care facilities, retail pharmacies and hospital pharmacies serving ambulatory and discharged patients.
OMCL: 32.63 (-0.27)

Saratoga Hospital Selects Omnicell Unity Enterprise Platform to Upgrade Existing Medication Automation Solutions
PR Newswire - Tue Nov 04, 7:00AM CST
Omnicell, Inc., (NASDAQ: OMCL), today announced that Saratoga Hospital, located in Saratoga Springs, New York, has selected Omnicell to be its new provider of automated medication management solutions and data analytics tools in the main hospital facility as well as an urgent care center, surgery center, infusion center and cancer treatment center. For the first time, from a single central pharmacy location, several different medication dispensing systems can be managed at Saratoga Hospital, providing greater efficiency to clinical and administrative staff.
OMCL: 32.63 (-0.27)

Omnicell Gains Despite Earnings Miss; View Up on High Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 10:20AM CST
Omnicell's (OMCL) share prices have climbed 7.3% since the earnings release to close at $32.31 on Friday
AMSG: 49.03 (-0.16), USPH: 40.43 (-0.41), RDNT: 8.59 (+0.17), OMCL: 32.63 (-0.27)

Omnicell misses 3Q profit forecasts
Automated Insights - Thu Oct 30, 6:37PM CDT
MOUNTAIN VIEW, Calif. (AP) _ Omnicell Inc. (OMCL) on Thursday reported profit of $7.3 million in its third quarter.
OMCL: 32.63 (-0.27)

Omnicell's (OMCL) CEO Randall Lipps on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Oct 30, 6:30PM CDT

OMCL: 32.63 (-0.27)

Omnicell misses by $0.01
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 3:34PM CDT

OMCL: 32.63 (-0.27)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Alibaba Lawsuit Deadline Puts Disclosure Risk in Focus

Updated Category News Views 180

A calendar deadline is doing more work than any earnings headline for Alibaba shareholders this week. A securities class action notice says investors who bought or acquired Alibaba Group Holding Limited securities between May 23, 2024 and November 11, 2026 may seek appointment as lead plaintiff by January 19, 2027. That is a procedural milestone, not a verdict, and...

Continue Reading
Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 154

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 71

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 157

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Epic Blue Puts $50,000 of Marketing Work to Use Locally

Updated Category News Views 136

A $50,000 pile of donated know-how can look soft on a spreadsheet, until you remember how often a small nonprofit or early-stage outfit gets ignored because it cannot afford someone to sharpen its message. Epic Blue Marketing, a women-owned firm based in Jackson, Michigan, says it provided that amount in donated and reduced-rate marketing, communications and public...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 154

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 27

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
Kyverna Probe Reopens IPO Disclosure Questions for Investors

Updated Category News Views 93

Clinical-trial caveats have a nasty habit of becoming shareholder headaches years later. Kyverna Therapeutics is back in that uncomfortable zone after Kahn Swick & Foti said it has opened an investigation into whether the company’s officers and directors breached fiduciary duties or otherwise violated state or federal law. For holders of KYTX, this is not a verdict and...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 129

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
Maryland Handgun Ban Suit Puts Ruger in Legal Crossfire

Updated Category News Views 150

A January Deadline With Real Commercial Teeth Maryland has turned a trigger-design dispute into a fresh legal and retail headache, and the clock is not polite about it. The National Shooting Sports Foundation filed suit against the state over S.B. 334, which is scheduled to take effect Jan. 1, 2027. The law bars sales of certain pistols with cruciform trigger bars,...

Continue Reading

Top 5 Most Recently Viewed Articles

Coca-Cola's Emerging Markets Strategy Fuels Long-Term Growth

Updated Category News Views 929

Coca-Cola's Position in Emerging Markets Coca-Cola Co (NYSE: KO) stands as a beacon of growth, with a visionary strategy that highlights both immediate and long-term opportunities. The company has successfully positioned itself in vital markets, particularly in North America and Latin America, which have proven central to its success. According to recent insights from...

Continue Reading
Voda IQ Appoints Armando Piccinini to Drive European Sales

Updated Category News Views 121

Voda IQ dropped some big news back in 2024 when they appointed Armando Piccinini as their European Sales Director. This guy’s got over twenty years under his belt in aquatic conservation, which they clearly hope will ramp up their sales strategy across Europe. But you gotta wonder—are the numbers behind this move really there? Can Experience Translate to Sales Growth?...

Continue Reading
Magnera Corporation to Shine at Upcoming Finance Conference

Updated Category News Views 163

Magnera Corporation's Conference Participation Announcement Magnera Corporation (NYSE: MAGN) has made an exciting announcement regarding its upcoming participation in a significant financial event. The company is set to be a part of the 2025 Bank of America Leveraged Finance Conference, aimed at fostering connections with top institutional investors. The event will take...

Continue Reading
Bullish Momentum Unveiled: Insights on Merck & Co Stocks

Updated Category News Views 180

Exciting Developments in Merck & Co Options Activity Notable investors are expressing strong optimism about Merck & Co. A recent analysis of options trading strategies reveals a wave of activity among traders aiming to capitalize on this potential. Options Trading Overview When reviewing the options history for Merck & Co (NYSE: MRK), we found a total of 33 trades that...

Continue Reading
Gilead Snags Arcellx: A High-Stakes Cancer Gamble Unfolds

Updated Category News Views 195

The Big Play for Cancer Innovation Gilead Sciences Inc. (NASDAQ:GILD) pulled the trigger on a pretty huge acquisition deal, landing Arcellx Inc. (NASDAQ:ACLX) this past Monday for a staggering $115 per share, which gets better with a potential extra $5 per share on a contingent value right. That rings in a hefty total of $7.8 billion—no pocket change, folks. What’s...

Continue Reading